Analyzing tumor and blood samples to understand DNA changes in lung cancer patients
EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood
This study looks at tumor and blood samples from lung cancer patients to see if certain DNA changes can help us understand their treatment outcomes better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of California, Davis Academic / other |
| Locations | 1 site (Sacramento, California) |
| Trial ID | NCT00899405 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on analyzing tumor tissue and blood samples from patients diagnosed with lung cancer to investigate DNA changes, specifically looking at mutations in the EGFR pathway. By examining these samples, researchers aim to correlate the presence of EGFR mutations with clinical outcomes in patients. The study utilizes PCR techniques to detect these mutations, providing insights that may enhance understanding of lung cancer biology and treatment responses.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with histologically or cytologically confirmed lung cancer.
Not a fit: Patients without a confirmed diagnosis of lung cancer or those who have not received prior EGFR inhibitors may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved identification of biomarkers that inform treatment decisions for lung cancer patients.
How similar studies have performed: Other studies examining DNA mutations in lung cancer have shown promising results, indicating that this approach is supported by prior research.
Eligibility criteria
Show full inclusion / exclusion criteria
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed lung cancer PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * May have received prior EGFR inhibitors
Where this trial is running
Sacramento, California
- University of California Davis Cancer Center — Sacramento, California, United States (Recruiting)
Study contacts
- Principal investigator: Philip C. Mack, PhD — University of California, Davis
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.